Last reviewed · How we verify
KN026
KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.
KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells. Used for HER2-positive gastric cancer, HER2-positive breast cancer.
At a glance
| Generic name | KN026 |
|---|---|
| Also known as | Docetaxel, KN046, IO therapy |
| Sponsor | Shanghai JMT-Bio Inc. |
| Drug class | Bispecific monoclonal antibody |
| Target | HER2 and HER3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
KN026 functions as a bispecific monoclonal antibody designed to engage both HER2 and HER3 on the surface of tumor cells, preventing ligand-induced activation and downstream proliferation signals. By targeting two complementary receptors in the HER family, it aims to overcome resistance mechanisms that can develop with single-target HER2 inhibitors. This dual-targeting approach is intended to provide enhanced anti-tumor activity in HER2-expressing malignancies.
Approved indications
- HER2-positive gastric cancer
- HER2-positive breast cancer
Common side effects
- Infusion-related reactions
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
- A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (PHASE2, PHASE3)
- JSKN003 Combined Treatment of HER2-positive Gastric Cancer (PHASE2)
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. (PHASE3)
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer (PHASE3)
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC (PHASE2)
- KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor (PHASE1)
- KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |